Novo Nordisk and Novartis put Victoza patent suit to bed, teeing up Sandoz copycat by 2024

cafead

Administrator
Staff member
  • cafead   Mar 23, 2022 at 11:02: AM
via After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo Nordisk’s aging GLP-1 mainstay.

Novo Nordisk and Novartis’ Sandoz have settled a patent infringement lawsuit covering the Danish drugmaker’s diabetes blockbuster Victoza, according to court documents filed Tuesday in the U.S. District Court for the District of Delaware.

article source
 

<